Abstract
Background
The present study was undertaken to evaluate the clinical impact of a thyroglobulin (Tg) minirecovery test (Tg-mRec) in a large series of differentiated thyroid carcinoma (DTC) patients treated and monitored homogeneously in a tertiary referral center.
Methods
Included were 1120 serum samples from 798 DTC patients. Tg, Tg autoantibodies (TgAb) and Tg-mrec measurements were performed on the automated Kryptor® platform and results compared to the corresponding clinical status.
Results
Among included samples 228 (20%) were TgAb-positive (TgAb+) and 892 (80%) TgAb-negative (TgAb−), respectively. Tg cutoff points were settled at 0.31 μg/L and 0.15 μg/L for TgAb− and TgAb+ patients, respectively, by ROC curve analysis. The diagnostic performance of serum Tg was reduced in TgAb+ compared to TgAb− patients, however, 87% of TgAb+ patients with recurrent disease and, particularly, all patients with distant metastases were correctly detected by adopting an optimized Tg cutoff for TgAb+ patients. A disturbed recovery was found in only 1% of TgAb− patients and in these cases no clinically relevant information was added by the Tg-mRec. Among TgAb+ patients with undetectable Tg and undisturbed Tg-mRec, no one had recurrent disease. However, a falsely undetectable Tg was demonstrated in two patients with recurrent disease who next to increased TgAb also had a disturbed Tg-mRec test.
Conclusions
There is no additional clinical benefit from performing Tg-mRec in most patients. It can however be considered in TgAb+ patients with undetectable Tg levels as it may help differentiate between patients with true negative and false negative Tg levels in the presence of such antibodies.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: None declared.
Honorarium: None declared.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
References
1. Grebe SK. Diagnosis and management of thyroid carcinoma: focus on serum thyroglobulin. Exp Rev Endocrinol Metab 2009;4:25–43.10.1586/17446651.4.1.25Search in Google Scholar
2. Spencer C, LoPresti J, Fatemi S. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. Curr Opin Endocrinol Diabetes Obes 2014;21:394–404.10.1097/MED.0000000000000092Search in Google Scholar PubMed PubMed Central
3. Giovanella L, Treglia G, Sadeghi R, Trimboli P, Ceriani L, Verburg FA. Unstimulated highly sensitive thyroglobulin in follow-up of differentiated thyroid cancer patients: a meta-analysis. J Clin Endocrinol Metab 2014;99:440–7.10.1210/jc.2013-3156Search in Google Scholar PubMed
4. Giovanella L, Clark PM, Chiovato L, Duntas L, Elisei R, Feldt-Rasmussen U, et al. Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. Eur J Endocrinol 2014;171:R33–46.10.1530/EJE-14-0148Search in Google Scholar PubMed PubMed Central
5. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, Lo Presti JS. Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. J Clin Endocrinol Metab 2005;90:5566–75.10.1210/jc.2005-0671Search in Google Scholar PubMed
6. Verburg FA, Luster M, Cupini C, Chiovato L, Duntas L, Elisei R, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: A Clinical Position Statement. Thyroid 2013; 23:1211–25.10.1089/thy.2012.0606Search in Google Scholar PubMed
7. Giovanella L, Feldt-Rasmussen U, Verburg FA, Grebe SK, Plebani M, Clark PM. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. Clin Chem Lab Med 2015;53:1301–14.10.1515/cclm-2014-0813Search in Google Scholar PubMed
8. Spencer C, Petrovic I, Fatemi S, LoPresti J. Serum thyroglobulin (Tg) monitoring of patients with differentiated thyroid cancer using sensitive (second-generation) immunometric assays can be disrupted by false-negative and false-positive serum thyroglobulin autoantibody misclassifications. J Clin Endocrinol Metab;99:4589–99.10.1210/jc.2014-1203Search in Google Scholar PubMed PubMed Central
9. Spencer CA. Clinical review: clinical utility of thyroglobulin antibody (TgAb) measurements for patients with differentiated thyroid cancers (DTC). J Clin Endocrinol Metab 2011;96:3615–27.10.1210/jc.2011-1740Search in Google Scholar PubMed
10. Okosieme OE, Evans C, Moss L, Parkes AB, Premawardhana LD, Lazarus JH. Thyroglobulin antibodies in serum of patients with differentiated thyroid cancer: relationship between epitope specificities and thyroglobulin recovery. Clin Chem 2005;51:729–34.10.1373/clinchem.2004.044511Search in Google Scholar PubMed
11. Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003;13:3–126.10.1089/105072503321086962Search in Google Scholar PubMed
12. Katrangi W, Grebe SK, Algeciras-Schimnich A.. Analytical and clinical performance of thyroglobulin autoantibody assays in thyroid cancer follow-up. Clin Chem Lab Med 2017;55:1987–94.10.1515/cclm-2017-0034Search in Google Scholar PubMed
13. Spencer C, Petrovic I, Fatemi S. Current thyroglobulin autoantibody (TgAb) assays often fail to detect interfering TgAb that can result in the reporting of falsely low/ undetectable serum Tg IMA values for patients with differentiated thyroid cancer. J Clin Endocrinol Metab 2011;96:1283–91.10.1210/jc.2010-2762Search in Google Scholar PubMed
14. Giovanella L, Toffalori E, Tozzoli R, Caputo M, Ceriani L, Verburg FA. Multiplexed immunoassay of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. Head Neck 2012;34:1369–71.10.1002/hed.21933Search in Google Scholar PubMed
15. Cubero JM, Rodriguez-Espinosa J, Gelpi C, Estorch M, Corcoy R. Thyroglobulin autoantibody levels below the cut-off for positivity can interfere with thyroglobulin measurement. Thyroid 2003;13:659–61.10.1089/105072503322240013Search in Google Scholar PubMed
16. Krahn J, Dembinski T. Thyroglobulin and anti-thyroglobulin assays in thyroid cancer monitoring. Clin Biochem 2009;42:416–9.10.1016/j.clinbiochem.2008.12.017Search in Google Scholar PubMed
17. Giovanella L, Keller F, Ceriani L, Tozzoli R. Heterophile antibodies may falsely increase or decrease thyroglobulin measurement in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2009;47:952–4.10.1515/CCLM.2009.230Search in Google Scholar PubMed
18. Netzel BC, Grebe SK, Carranza Leon BG, Castro MR, Clark PM, Hoofnagle AN, et al. Thyroglobulin (Tg) testing revisited: Tg assays, TgAb assays, and correlation of results with clinical outcomes. J Clin Endocrinol Metab 2015;100: 1074–83.10.1210/jc.2015-1967Search in Google Scholar PubMed PubMed Central
19. Azmat U, Porter K, Senter L, Ringel MD, Nabhan F. Thyroglobulin liquid chromatography-tandem mass spectrometry has a low sensitivity for detecting structural disease in patients with antithyroglobulin antibodies. Thyroid 2017;27:74–80.10.1089/thy.2016.0210Search in Google Scholar PubMed PubMed Central
20. Dufour M. Thyroglobulin antibodies-failing the test. J Clin Endocrinol Metab 2011;96:1276–8.10.1210/jc.2011-0681Search in Google Scholar PubMed
21. Verburg FA, Hartmann D, Grelle I, Giovanella L, Buck AK, Reiners C. Relationship between antithyroglobulin autoantibodies and thyroglobulin recovery rates using different thyroglobulin concentrations in the recovery buffer. Horm Metab Res 2013;45:728–35.10.1055/s-0033-1349890Search in Google Scholar PubMed
22. Verburg FA, Grelle I, Giovanella L, Reiners C. Evaluation of the BRAHMS Kryptor® thyroglobulin “mini-recovery” test in thyroid healthy subjects. Horm Metab Res 2012;44:555–7.10.1055/s-0032-1314804Search in Google Scholar PubMed
23. Giovanella L, Imperiali M, Verburg FA, Ceriani L. Evaluation of the BRAHMS Kryptor® thyroglobulin minirecovery test in patients with differentiated thyroid carcinoma. Clin Chem Lab Med 2013;51:449–53.10.1515/cclm-2012-0378Search in Google Scholar PubMed
24. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016;26:1–133.10.1089/thy.2015.0020Search in Google Scholar PubMed PubMed Central
25. Trimboli P, Zilioli V, Imperiali Mì, Ceriani L, Giovanella L. High-sensitive basal serum thyroglobulin 6–12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas. Eur J Endocrinol 2017;176:497–504.10.1530/EJE-16-1011Search in Google Scholar PubMed
26. Giovanella L, Imperiali M, Verburg FA, Trimboli PP. Early post-treatment risk stratification of differentiated thyroid cancer: comparison of three high-sensitive Tg assays. Eur J Endocrinol 2018;178:77–84.10.1530/EJE-17-0663Search in Google Scholar PubMed
©2019 Walter de Gruyter GmbH, Berlin/Boston
